For the full BPC-157 dosing breakdown, see our BPC-157 dosage protocol guide: BPC-157: 200 to 500 mcg per day, subcutaneous injection near the injury site, 4 to 8 weeks TB-500 loading phase (Weeks 1-4): 2 to 5 mg twice per week TB-500 maintenance phase (Weeks 5-8): 2 mg once per week Route: Both peptides are administered via subcutaneous injection
Turoverov et al., 2019
They outline practical, staged approaches for homes and vehiclesaddressing moisture control, HVAC/duct hygiene, dust removal, and targeted decontamination of mycotoxins/VOCsto complement or follow traditional remediation
The oral route delivers BPC-157 through the GI tract, which is where the original peptide sequence was identified and where its gastroprotective properties are most mechanistically direct
Local injection site reactions were uncommon in the Phase 2 trial, occurring at a lower frequency than systemic gastrointestinal events
We discovered that Diphenyleneiodonium chloride (DPI), an inhibitor of flavoprotein enzymes and mitochondrial complex I, synergizes with mitoquinone mesylate (MitoQ), a mitochondria-targeted antioxidant in 2D and 3D in vitro models of NB
